It was supposed that specific knockdown effects could be maintained and

strengthened in this way without severe toxicities that have been reported to come with the use of short bursts of high-dose DNA/liposome complex [28]. Based on the same consideration about toxicity, DDP was administered in a similar way. It was given to the mice at the dose of 2 mg/kg twice a week instead of at maximum tolerated dose(9 mg/kg/week)[29]. In this study, the enhanced efficacy without overt toxicity suggested the effectiveness of the dosing/scheduling strategy. The success of gene therapy is highly dependent on delivery vector. In this study, we elected THZ1 mw the cationic liposome DOTAP:Chol as the delivery vector. It is a well-characterized nonviral vector and has been advanced into phase I clinical trial for treatment of NSCLC [30–32]. In this study, attenuation of VEGF expression in vivo confirmed the successful delivery of DOTAP:Chol. Conclusions In summary, our study shows that the combination of plasmid-encoding VEGF shRNA and low-dose DDP is highly effective in inhibiting MGCD0103 supplier NSCLC growth in vivo without overt toxicity. The enhanced antitumor

efficacy may be attributed to synergistic mechanisms of decreased www.selleckchem.com/products/ly2109761.html angiogenesis and increased induction of apoptosis. Our findings suggest the potential use of the combined approach in treatment of lung cancer. Acknowledgements This work is supported by The National Key Basic Research Program (973 Program) of China (2010CB529900), Hi-tech Research and Development Program (863 Program) of China

(2007AA021008) and New Drugs Research and Development Importance Special Program (2009ZX09102-241). References 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71–96.PubMedCrossRef 2. Felip E, Cedres S, Peralta S, Prat A: Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). Ann Oncol 2007,18(Suppl Branched chain aminotransferase 9):143–146. 3. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182–1186.PubMedCrossRef 4. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669–676.PubMedCrossRef 5. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249–257.PubMedCrossRef 6. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593–4599.PubMed 7. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et al.: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271–7278.PubMedCrossRef 8. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al.